Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-30T23:24:10.188Z Has data issue: false hasContentIssue false
  • English
  • Français

Weight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia

Published online by Cambridge University Press:  28 April 2022

Jonathan M. Meyer ,
Leona Bessonova ,
Haley S. Friedler ,
Kathleen M. Mortimer ,
Harry Cheng ,
Thomas Brecht ,
Amy K. O’Sullivan ,
Hannah Cummings ,
David McDonnell  and
Michael J. Doane
Jonathan M. Meyer
Affiliation:
San Diego School of Medicine, University of California, La Jolla, CA, USA
Leona Bessonova
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Haley S. Friedler
Affiliation:
OM1, Inc., Boston, MA, USA
Kathleen M. Mortimer
Affiliation:
OM1, Inc., Boston, MA, USA
Harry Cheng
Affiliation:
OM1, Inc., Boston, MA, USA
Thomas Brecht
Affiliation:
OM1, Inc., Boston, MA, USA
Amy K. O’Sullivan
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Hannah Cummings
Affiliation:
Alkermes, Inc., Waltham, MA, USA
David McDonnell
Affiliation:
Alkermes Pharma Ireland Ltd., Dublin, Ireland
Michael J. Doane
Affiliation:
Alkermes, Inc., Waltham, MA, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

Clinically significant weight gain (CSWG) is associated with increased morbidity and mortality. This study describes CSWG and comorbidities observed in patients with bipolar I disorder (BD-I) and schizophrenia (SZ) after initiating select second-generation antipsychotics (SGAs).

Methods

Percent change in weight, CSWG (=7% weight increase), and incident comorbidities within 12 months of treatment were assessed among patients initiating oral SGAs of moderate-to-high weight gain risk using medical records/claims (OM1 Real-World Data Cloud; January 2013-February 2020). Oral SGAs included clozapine (SZ), iloperidone (SZ), paliperidone (SZ), olanzapine, olanzapine/fluoxetine (BD-I), quetiapine, and risperidone. Outcomes were stratified by baseline body mass index and reported descriptively.

Results

Among patients with BD-I (N = 9142) and SZ (N = 8174), approximately three-quarters were overweight/obese at baseline. During treatment (mean duration = 30 weeks), average percent weight increase was 3.7% (BD-I) and 3.3% (SZ). Average percent weight increase was highest for underweight/normal weight patients (BD-I = 5.5%; SZ = 4.8%), followed by overweight (BD-I = 3.8%; SZ = 3.4%) and obese patients (BD-I = 2.7%; SZ = 2.3%). Within 3 months of treatment, 12% of all patients experienced CSWG. A total of 11.3% (BD-I) and 14.7% (SZ) of patients developed coronary artery disease, hypertension, dyslipidemia, or type 2 diabetes within 12 months of treatment; development of comorbidities was highest among overweight/obese patients and those with CSWG.

Conclusions

Patients who were underweight/normal weight at baseline had the greatest percent change in weight during treatment. Increased comorbidities were observed within 12 months of treatment, specifically among overweight/obese patients and those with CSWG. The magnitude of weight gain and development of comorbidities were similar for patients with BD-I and SZ.

Funding

Alkermes, Inc.

Type
Abstracts
Information
CNS Spectrums , Volume 27 , Issue 2 , April 2022 , pp. 240
Copyright
© The Author(s), 2022. Published by Cambridge University Press